Customized stem cells for clinical application in blood disorders

$1,193,861R24FY2013DKNIH

Boston Children'S Hospital, Boston MA

Investigators

George Q Daleycontact James J Collins Leonard I Zon

Linked publications & trials

Paper 37126722 Paper 37119815 Paper 36227997 Paper 36137040 Paper 35931029 Paper 34939923 Paper 34143974 Paper 34114603 Paper 33986176 Paper 33741760 Paper 33264224 Paper 33230299 Paper 33087503 Paper 32883883 Paper 32810442 Paper 32749922 Paper 32302558 Paper 32032546 Paper 31267104 Paper 30728174 Paper 30622145 Paper 30504234 Paper 30425071 Paper 30209067 Paper 30139917 Paper 30089629 Paper 29899448 Paper 29739946 Paper 29625070 Paper 29497036 Paper 29342143 Paper 29212039 Paper 29117894 Paper 28846095 Paper 28830909 Paper 28822771 Paper 28702683 Paper 28617813 Paper 28591648 Paper 28514439 Paper 28416284 Paper 28351983 Paper 28179501 Paper 28129862 Paper 28126924 Paper 28009288 Paper 27870830 Paper 27554085 Paper 27443926 Paper 27401346 Paper 27341538 Paper 27257760 Paper 27095787 Paper 26905203 Paper 26416685 Paper 26385351 Paper 26214132 Paper 25870201 Paper 25870200 Paper 25870199 Paper 25762177 Paper 25752963 Paper 25714926 Paper 25668787 Paper 25594182 Paper 25587036 Paper 25485572 Paper 25471879 Paper 25437882 Paper 25324523 Paper 25126793 Paper 25126792 Paper 25094063 Paper 24914562 Paper 24813856 Paper 24286030 Paper 24240475 Paper 24209627 Paper 24094326 Paper 24076116 Paper 23673969 Paper 23620514 Paper 23602541 Paper 23327523 Paper 23277278 Paper 23122293 Paper 23122286 Paper 22901255 Paper 22840998 Paper 22704514 Paper 22424223 Paper 22388813 Paper 21466798

Abstract

DESCRIPTION (provided by applicant): This proposal brings together an interdisciplinary team of collaborators to address a major challenge: to achieve clinical utility of patient-specific induced pluripotent stem cells (iPSCs) for blood diseases. Our ultimate goal is to differentiate customized iPSCs into hematopoietic stem and progenitor cells to accurately model human blood diseases for research into disease mechanisms, and as a platform for treating patients with blood diseases. To achieve this, this proposal aims to discover the developmental pathways and biomechanical principles that drive the formation of hematopoietic stem cells (HSCs) in embryos, and will screen for morphogens and chemicals that promote hematopoietic maturation in vitro. We will take several novel and integrated approaches including: 1) application of predictive computational algorithms to gene expression data from highly purified embryonic HSC populations to discover the gene networks that direct hematopoietic and lymphoid development; 2) Screens in zebrafish embryos and murine and human pluripotent stem cells to discover novel chemical and biological regulators of HSCs; 3) bioengineered platforms for production of hematopoietic stem and progenitor populations, applying biomechanical forces to mimic the embryonic microenvironment; 4) derivation of iPSC from patients with Primary Immune Deficiency to correlate genotype with lymphoid phenotypes and to test strategies for gene repair through an in vitro clinical trial; and ultimately, 5) to derive transgene-free clinical-grade pluripotent stem cells, and develop protocols for differentiation of hematopoietic populations at clinical scale. Success in generating engraftable, genetically unperturbed HSC would be a significant breakthrough that would enhance the utility of iPSC for modeling hematopoietic disease and establish a translational platform for combining gene repair with HSC transplantation therapy.

View original record on NIH RePORTER →